Longeveron Appoints Nirav Jhaveri as Chief Financial Officer (Form 8-K)

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

MIAMI, Fla., August 19, 2026 -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company's executive leadership team in the role of Chief Financial Officer ("CFO"), principal financial officer and principal accounting officer. He succeeds Marie Washburn who stepped into the role following the retirement of the prior CFO. Ms. Washburn will return to her former role as the Company's Corporate Controller.

"I am delighted to welcome Nirav as Longeveron's Chief Financial Officer," said Steven H. Willard, Chief Executive Officer of Longeveron. "His significant experience in biotech company corporate finance and capital markets will be a tremendous asset as Longeveron continues to advance the development of our stem cell therapy across four indications, each addressing a significant unmet medical need. Our Phase 2b clinical trial evaluating laromestrocel as a potential treatment for HLHS, a devastating rare pediatric and orphan designated indication, is anticipated to produce top-line trial results in September of this year."

Mr. Jhaveri commented, "I am incredibly excited to join the Company at this potentially transformational period in its history. With strong initial data across multiple indications, I believe Longeveron is well positioned to be a leader in advancing the adoption of stem cell therapy in healthcare. I look forward to working closely with Steve, the Board of Directors and the entire Longeveron team to ensure the long-term success of laromestrocel while enhancing the Company's operational functions."

Mr. Jhaveri has served as Chief Financial Officer at public and venture-backed biotech companies, with over 25 years of experience in capital markets, corporate finance, business development, and investor relations, including over 15 years in the biotech sector, and a track record across capital raising, licensing and M&A transactions, and IPO readiness.

Before joining Longeveron, Mr. Jhaveri served as CFO of Opus Genetics (Nasdaq: IRD), a gene therapy company focused on inherited retinal diseases; Insilico Medicine (HKEX: 3696.HK), an AI-driven drug discovery company; and Journey Medical Corporation (Nasdaq: DERM), a commercial-stage dermatology company. Earlier in his career, Mr. Jhaveri held roles in business development at Fortress Biotech, equity research at Citigroup, and investment banking at Bank of America. He is a CFA (Chartered Financial Advisor) charterholder.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company's lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important U.S. FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.